Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT01473251 Completed - Clinical trials for Diabetic Macular Edema

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

NCT ID: NCT01448538 Completed - Clinical trials for Wet Macular Degeneration

Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany

Start date: August 2011
Phase: N/A
Study type: Observational

In the research study an observation of patients with wet age-related macular degeneration (wet AMD) will be performed. The term observational study indicates that the current course of therapy and the associated circumstances will be recorded. In this study, no medical care is changed. Also, no new drugs are tested. This study is being conducted in about 30 centers in Germany. A total of approximately 500 patients will be enrolled. The study is designed for a period of 12 months. At the beginning and end of the study the physician will document the patient data. Therefore will be used information from the patient records and documented visits. If such information is not available in the study center, the otherwise attending ophthalmologist will be consulted about the vision acuity values and visits in the observation period. Furthermore, patients are asked to participate in three telephone interviews and fill out during their visits to the study center a short questionnaire about their current vision and their well-being. In the telephone interviews will be discussed with the patient about his wet AMD disease and its treatment, its experience and its perspectives as well as any problems occur.

NCT ID: NCT01414153 Completed - Clinical trials for Exudative Age-related Macular Degeneration

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Nexus
Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD). iSONEP not only has an anti-permeability effect, but also has anti-angiogenic, anti-inflammatory, and anti-fibrotic properties. The drug may therefore have the ability to achieve better visual outcomes than Lucentis, Avastin or Eylea, particularly in those subjects who do not demonstrate a robust response to Lucentis, Avastin or Eylea after several monthly injections. Further, the combination of Lucentis, Avastin or Eylea and iSONEP may be additive or synergistic. By inhibiting the multiple mechanisms that contribute to exudative-AMD-related vision loss, better visual outcomes may be possible than with Lucentis, Avastin or Eylea alone.

NCT ID: NCT01404845 Completed - Clinical trials for Exudative Age-related Macular Degeneration

Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation

Start date: September 2011
Phase: N/A
Study type: Interventional

•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries. The macular pigment, composed of carotenoid derivatives (lutein and zeaxanthin), may play an important role in the occurrence of AMD. An increase in macular pigment following dietary supplementation with lutein and zeaxanthin could allow early treatment with such supplements in subjects with a high risk of AMD, and encourage them to change their eating habits. •Primary outcome: Comparative analysis of the density and evolution of the density of macular pigment: - In patients without any retinal pathology who underwent cataract surgery 1 month previously - In the non-exudative eye of patients with exudative AMD in one eye by analyzing the density and evolution of the density of macular pigment in the non-exudative eye - Secondary outcomes: Analysis of changes in macular pigment density after taking food supplements (Nutrof Total versus comparator): - Time taken to reach the maximum plateau of macular pigment density (no increase in density between 2 measurements) - Time taken to return to the baseline macular pigment density after cessation of supplementation - Study design : Pilot study -Prospective, randomised, double-masked, comparative, multicenter.

NCT ID: NCT01362348 Terminated - Clinical trials for Macular Degeneration

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Start date: July 7, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.

NCT ID: NCT01334255 Terminated - Clinical trials for Pigment Epithelial Detachment

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

PED
Start date: March 2011
Phase: Phase 1
Study type: Interventional

LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary to PED Secondary to Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV).

NCT ID: NCT01327222 Completed - Clinical trials for Age Related Macular Degeneration

Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

LOW-VISION
Start date: February 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.

NCT ID: NCT01306591 Completed - Clinical trials for Exudative Age-related Macular Degeneration

Bevacizumab for Neovascular Age-related Macular Degeneration

Start date: January 2008
Phase: N/A
Study type: Interventional

Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.

NCT ID: NCT01304693 Completed - Clinical trials for Exudative Age-Related Macular Degeneration

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative age-related macular degeneration (AMD).

NCT ID: NCT01291121 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion

Start date: February 2011
Phase: N/A
Study type: Interventional

The main objective is to determine the efficacy of intravitreal administration of Ranibizumab combined with intravitreous injection of expansile gas and induction of posterior vitreous detachment on best-corrected visual acuity and ocular coherence tomography (OCT) macular thickness in subjects with neovascular age-related macular degeneration (AMD) with posterior vitreomacular adhesion (VMA). Secondary objectives are to assess the safety and tolerability of the intravitreal administration of Ranibizumab combined with intravitreous injection of expansile gas.